Pfizer Declined Researching A Drug That Showed Real Signs Of Slowing Alzheimers

It’s just come out that Pfizer declined to run a trial on one of their existing drugs that showed signs of having a 64% chance of reducing the risk of Alzheimers disease. The trial would have cost $80 million so they decided not to do it. It was more important for them to fiure out how to market a new oxy that taste like skittles.

Read more at washigntonpost.com.

Pfizer kept quiet about a drug that could potentially reduce the risk of Alzheimer’s, Washington Post reports

Read More Stories From the IB Wire

.

.